2-(2,6-Dichloro-benzyl)-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester | 736971-53-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2,6-Dichloro-benzyl)-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester
• 英文别名: methyl 2-[(2,6-dichlorophenyl)methyl]-4,5-dihydro-1H-imidazole-5-carboxylate
• CAS: 736971-53-2
• 化学式: C₁₂H₁₂Cl₂N₂O₂
• 分子量: 287.145
• InChiKey: RMBSVHZUVYVAJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2,6-Dichloro-benzyl)-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester 在 manganese(IV) oxide 、 sodium hydroxide 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(2,6-dichloro-benzyl)-1H-imidazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide
  参考文献：
  名称：

  Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists

  摘要：

  A thiazole derivative, 2-(2,6-dichlorobenzyl)-N-(4-isopropylphenyl) thiazole-4-carboxamide (1), was identified as a TRPV1 antagonist. We synthesized various thiazole analogs and evaluated them for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. The IC50 values of the most potent antagonists were ca. 0.050 mu M in these assays. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.100
• 作为产物：
  描述：

  methyl 2,3-diaminopropionate hydrochloride 、 2-(2,6-Dichloro-phenyl)-acetimidic acid methyl ester 在 三乙胺 作用下， 以 甲醇 为溶剂， 以63%的产率得到2-(2,6-Dichloro-benzyl)-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists

  摘要：

  A thiazole derivative, 2-(2,6-dichlorobenzyl)-N-(4-isopropylphenyl) thiazole-4-carboxamide (1), was identified as a TRPV1 antagonist. We synthesized various thiazole analogs and evaluated them for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. The IC50 values of the most potent antagonists were ca. 0.050 mu M in these assays. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.100

文献信息

• Vanilloid receptor ligands and their use in treatments
  申请人：Amgen Inc.

  公开号：US20040157845A1

  公开（公告）日：2004-08-12

  Compounds having the general structure 1 and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  具有一般结构1的化合物及含有它们的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张型头痛、普通炎症、关节炎、风湿病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症症状、炎症性疼痛及相关的过敏症和痛觉过敏、神经痛及相关的过敏症和痛觉过敏、糖尿病性神经病痛、烧灼性疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿生殖、胃肠道或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、普通胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、头发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
• VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
  申请人：AMGEN INC.

  公开号：EP1603905A1

  公开（公告）日：2005-12-14
• US7265138B2
  申请人：——

  公开号：US7265138B2

  公开（公告）日：2007-09-04
• [EN] VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS<br/>[FR] LIGANDS DU RECEPTEUR VANILLOIDE ET LEUR UTILISATION DANS DES TRAITEMENTS
  申请人：AMGEN INC

  公开号：WO2004072068A1

  公开（公告）日：2004-08-26

  Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
• Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists
  作者：Ning Xi、Yunxin Bo、Elizabeth M. Doherty、Christopher Fotsch、Narender R. Gavva、Nianhe Han、Randall W. Hungate、Lana Klionsky、Qingyian Liu、Rami Tamir、Shimin Xu、James J.S. Treanor、Mark H. Norman

  DOI：10.1016/j.bmcl.2005.08.100

  日期：2005.12

  A thiazole derivative, 2-(2,6-dichlorobenzyl)-N-(4-isopropylphenyl) thiazole-4-carboxamide (1), was identified as a TRPV1 antagonist. We synthesized various thiazole analogs and evaluated them for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. The IC50 values of the most potent antagonists were ca. 0.050 mu M in these assays. (c) 2005 Elsevier Ltd. All rights reserved.